Journal
INFLAMMATORY BOWEL DISEASES
Volume 20, Issue 2, Pages 389-397Publisher
OXFORD UNIV PRESS INC
DOI: 10.1097/01.MIB.0000437616.37000.41
Keywords
inflammatory bowel disease; cytokines; interleukins
Categories
Funding
- National Institutes of Health, National Cancer Institute
- Crohn's and Colitis Foundation of America
Ask authors/readers for more resources
Inflammatory bowel disease accounts for significant patient morbidity in the Western world. Several immunosuppressive therapies are available but are associated with potential significant adverse effects. In addition, there remains a cohort of patients with refractory or relapsing disease. Therefore, the search for novel therapeutic agents continues. In this review, we evaluate the role of a number of designated cytokines that are candidates in the pathogenesis of inflammatory bowel disease and discuss how their manipulation has been explored as a therapeutic strategy for this disease. The interleukins (ILs) chosen for discussion reflect those that currently show most promise as future therapeutic targets, as well as discussing the role of some of the most recently identified ILs, such as IL-27, IL-33, IL-35, and IL-22, in this context.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available